title: Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials.
abstract: About a third of patients with ovarian cancer present with localized disease; despite surgical resection, up to half the tumors recur. Since it has not been established whether adjuvant treatment can benefit such patients, we conducted two prospective, randomized national cooperative trials of adjuvant therapy in patients with localized ovarian carcinoma (International Federation of Gynecology and Obstetrics Stages Ia to IIc). All patients underwent surgical resection plus comprehensive staging and, 18 months later, surgical re-exploration. In the first trial, 81 patients with well-differentiated or moderately well differentiated cancers confined to the ovaries (Stages Iai and Ibi) were assigned to receive either no chemotherapy or melphalan (0.2 mg per kilogram of body weight per day for five days, repeated every four to six weeks for up to 12 cycles). After a median follow-up of more than six years, there were no significant differences between the patients given no chemotherapy and those treated with melphalan with respect to either five-year disease-free survival (91 vs. 98 percent; P = 0.41) or overall survival (94 vs. 98 percent; P = 0.43). In the second trial, 141 patients with poorly differentiated Stage I tumors or with cancer outside the ovaries but limited to the pelvis (Stage II) were randomly assigned to treatment with either melphalan (in the same regimen as above) or a single intraperitoneal dose of 32P (15 mCi) at the time of surgery. In this trial (median follow-up, greater than 6 years) the outcomes for the two treatment groups were similar with respect to five-year disease-free survival (80 percent in both groups) and overall survival (81 percent with melphalan vs. 78 percent with 32P; P = 0.48). We conclude that in patients with localized ovarian cancer, comprehensive staging at the time of surgical resection can serve to identify those patients (as defined by the first trial) who can be followed without adjuvant chemotherapy. The remaining patients with localized ovarian cancer should receive adjuvant therapy, and with adjuvant melphalan or intraperitoneal 32P should have a five-year disease-free survival of about 80 percent.
authors.affiliation: Gynecologic Oncology Group, Philadelphia, PA.
authors.forename: R C
authors.initials: RC
authors.lastname: Young
authors.forename: L A
authors.initials: LA
authors.lastname: Walton
authors.forename: S S
authors.initials: SS
authors.lastname: Ellenberg
authors.forename: H D
authors.initials: HD
authors.lastname: Homesley
authors.forename: G D
authors.initials: GD
authors.lastname: Wilbanks
authors.forename: D G
authors.initials: DG
authors.lastname: Decker
authors.forename: A
authors.initials: A
authors.lastname: Miller
authors.forename: R
authors.initials: R
authors.lastname: Park
authors.forename: F
authors.initials: F
authors.lastname: Major
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic
chemical_list: D010761:Phosphorus Radioisotopes; D008558:Melphalan